Processing your request


please wait...

 | Case Page

 | Case Page |

Case Page

 

Intercept Pharmaceuticals, Inc.

Case Summary

Intercept Pharmaceuticals, Inc. Securities Litigation

Case Summary

Case Status:    DISMISSED    
On or around 10/09/2020 (Other)

Filing Date: September 27, 2017

According to the law firm press release, the Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. The Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Ocaliva entailed undisclosed safety risks, including death, to patients suffering from PBC; and (ii) as a result of the foregoing, Intercept’s public statements were materially false and misleading at all relevant times.

On June 1, 2018, the Court issued an Order appointing Lead Plaintiffs and Counsel. Lead Plaintiffs filed an amended Complaint on July 31. Defendants filed a Motion to Dismiss the amended Complaint on September 14. On March 26, 2020, the Court issued an Order granting Defendants' Motion to Dismiss. On October 9, Lead Plaintiffs filed a notice appealing the Court's Dismissal Order.

Company & Securities Information

Defendant: Intercept Pharmaceuticals, Inc.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: ICPT
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

Judith DeSmet, et al. v. Intercept Pharmaceuticals, Inc., et al.

COURT: S.D. New York
DOCKET #: 17-CV-07371
JUDGE: Hon. Lewis A. Kaplan
DATE FILED: 09/27/2017
CLASS PERIOD START: 05/31/2016
CLASS PERIOD END: 09/20/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Pomerantz LLP (New York)
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Class Action Complaint 09/27/2017
2 U.S. District Court Civil Docket 06/01/2018
3 Order 06/01/2018

Reference Complaint

Hou Liu, et al. v. Intercept Pharmaceuticals, Inc., et al.

COURT: S.D. New York
DOCKET #: 17-CV-07371
JUDGE: Hon. Lewis A. Kaplan
DATE FILED: 07/31/2018
CLASS PERIOD START: 06/09/2016
CLASS PERIOD END: 09/20/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Faruqi & Faruqi LLP (New York)
Reference Complaint (REF) Filings:
No Document Title Filing Date
1 Amended Class Action Complaint 07/31/2018
2 Memorandum Opinion 03/26/2020
3 Judgment 03/27/2020
4 U.S. District Court Civil Docket 10/09/2020
5 Notice of Appeal 10/09/2020

Related District Court Filings

—Related District Court Filings Data is not available
 
 

Cases